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1. Introduction 
1.1 Multiple myeloma  
Multiple myeloma (MM) is a haematological disorder of malignant plasma cells. B 
lymphocytes start in the bone marrow and move to the lymph nodes.  
When they are activated to secrete antibodies, they are known as plasma cells, which are 
crucial part of the immune system. Due to the fundamental nature of the system affected, 
multiple myeloma manifests systemic symptoms that make it difficult to diagnose. Multiple 
myeloma is characterised by slow proliferation of the tumour cells, mainly in the bone 
marrow, by production of large amounts of immunoglobulins and osteolytic lesions. Multiple 
myeloma is a generally incurable disease at present, but remissions may be induced with stem 
cells transplants, steroids, chemotherapy and treatment with vincristine + doxorubicin + 
dexamethasone or thalidomide + dexamethasone or bortezomib based regimens or 
lenalidomide. The different therapeutic modalities have different “target location”. 
1.2 Epidemiology of multiple myeloma 
Multiple myeloma mainly affects older adults, but its causes and other risk factors are 
unknown. Yearly incidence is 3-6/100 000 worldwide, accounts for 1-2 % of all human 
cancer. Median survival is 50–55 months. 
1.3 The role of cytokines in the growth, progression and dissemination of multiple 
myeloma 
Cytokines are soluble proteins, peptides or glycoproteins that are released by cells. 
Cytokines can affect the cells via an autocrine and/or paracrine regulation mechanisms. In 
case of an autocrine regulation mechanism the endogenous produced cytokine affects the 
same type of cell. In case of a paracrine regulation mechanism the target cell is near to the 
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cytokine produced cell. Cytokine binds to a specific receptor and causes a change in 
function or in development (differentiation) of the target cell. In both cases, i.e. autocrine 
and paracrine regulation mechanisms the expression of the membrane receptor is altered. 
1.3.1 Interleukins are a group of cytokines which are produced by a wide variety of body 
cells. The majority of interleukins are synthesized by helper CD4+ T lymphocytes, 
monocytes/macrophages and by endothelial cells. If the produced cytokine is released, then 
it is measurable in the supernatant, if not then the cytokine is measurable only intracellular. 
Interleukin-6 (IL-6) originally defined as a B cell differentiation factor is produced by 
different cell types and certain tumour cells. Interleukin-6 acts as a pro-inflammatory and an 
anti-inflammatory cytokine. As a pro-inflammatory cytokine regulates inflammatory 
reactions either directly or indirectly. As an anti-inflammatory cytokine Interleukin-6 
reduces the inflammatory reactions. IL-6 exits in three molecular weights, i.e. 21-30 kDa, 
150-200 or 450 kDa. The biological activity of IL-6 depends on binding to its specific 
receptors. These membrane receptors composed the glycoprotein gp80 Interleukin-6 
receptor alpha (IL-6R, also called CD126) and a signal-transducing component gp130 (also 
called CD 130). The complex IL-6+IL-6R+gp130 initiate a signal transduction cascade 
through JAKs (Janus kinases) and STATs (Signal Transducer-Activator of Transcription). 
The membrane receptors are released from the cells as soluble receptor proteins (sIL-6R and 
sgp130). As agonist, sIL-6R enhances the biological activity of IL-6 and sgp130 is an 
antagonist against the complex IL-6+sIL-6R. 
Interleukin-6 is a major proliferative factor for the malignant plasma cells (multiple 
myeloma cells). This cytokine produces by the plasma cells and it affects the cells by an 
autocrine regulation mechanism with an additional paracrine signalling. IL-6 in a 
concentration of 2pg/ml can induce 50% proliferation in myeloma cells. 
The multiple myeloma cells can be classified into three groups depending on exogenous IL-
6: (a) both proliferation and survival of the cells are dependent on IL-6, (b) only proliferation 
of the myeloma cells is affected by IL-6, (c) the cells are dependent on IL-6 only for survival, 
but not for proliferation.  However there are also some cell lines that are independent of IL-6 
both for survival and proliferation. The serum values of IL-6 in 35% or in 97% or in 42% of 
multiple myeloma patients were significantly higher than in healthy persons (Nachbour et 
al., 1991; DuVillard et al., 1995; Wierzbowska et al., 1999).   
Because about 70% of the secreted IL-6 forms a complex with sIL-6R (Gaillard et al., 1987), 
the amount of the free IL-6 in serum is low. Therefore the serum level of the sIL-6R is an 
important parameter in the evaluation and in the progression of multiple myeloma 
(Papadaki et al., 1997; Wierzbowska et al., 1999).  
Interleukin-10 (IL-10) is known as a human cytokine synthesis inhibitory factor (CSIF). It 
produces by Thelper2 cells, monocytes/macrophages, by B lymphocytes and some tumour 
cells. Interleukin-10 has (1) immunosuppressive effect and (2) immunostimulatory effect. It 
down-regulates the expression of Thelper1 cytokines, MHC class II antigens and co-
stimulatory molecules on macrophages. Interleukin-10 is a pleiotropic cytokine which 
increases Bcl-2 levels and protects cells from steroid or doxorubicin-induced apoptosis.  
How might the presence of IL-10 contribute to a poor prognosis for some cancer? One 
possibility: Interleukin-10 is a growth factor for tumour cells. Second possibility: Interleukin-
10 suppresses the anti-tumour immune responses.  
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Interleukin-10 enhances the survival and proliferation of B cells. IL-10 is a growth factor for 
myeloma cells (Kovacs, 2010a), enhances the proliferation of freshly explanted myeloma 
cells in a short-term bone marrow culture (Lu et al., 1995). Three out of seven human 
myeloma cell lines produce IL-10. Elevated IL-10 levels were detected in serum from about 
50% of patients having multiple myeloma showing a relation to the clinical manifestation 
(Otsuki et al., 2000; 2002). Interleukin-6 leads to a marked production of Interleukin-10 in 
several human multiple myeloma cells. Interleukin-10 is an Interleukin-6 related growth 
factor for these tumour cells (Kovacs, 2010a). 
1.4 Cytostatic effect and cytocidal effect  
Cytocidal effect: It is known that there are two important pathways against tumours: To 
inhibit the tumour cell proliferation (cytostatic effect) and/or to induce the death of the 
tumour cells (cytocidal effect). Cytocidal effect: apoptosis or necrosis. 
The apoptosis is a physiological process in the life of healthy cells, whereas necrosis is a 
pathological process for tumour cells. Cytotoxicity is the quality of being toxic to cells. There 
are a direct and an indirect (cell-mediated) cytotoxicity. In case of direct cytotoxicity the 
cells are treated with cytotoxic compounds leading to necrosis.   
1.5 Viscum album (VA) extract 
Viscum album (VA) extract from European mistletoe plants has fermented and non-
fermented preparations. Active components of VA extracts include mistletoe lectins (I, II, III) 
and viscotoxin, additionally aminoacids, polysaccharides and lipids. The fermented 
preparations are used either alone or in combination with chemo/radiotherapy in the 
treatment of tumour patients.  
The Viscum album QuFrF (VAQuFrF) is an aqueous and unfermented extract of mistletoe 
plants growing in the oak tree. It contains 1 µg lectin and 6 µg viscotoxin in 5 mg/ml or 2 µg 
lectin and 10 µg viscotoxin in 10 mg/ml. The extract is an experimental drug that is not yet 
used in the treatment of tumour patients. 
1.6 Vincristine 
Vincristine is a vinca alkaloid. As a chemotherapeutic agent is used mainly in combination 
with other chemotherapeutic substances in the therapy of multiple myeloma. Vincristine 
inhibits the  proliferation of these tumour cells and as a CCS blocker (El Alaoui, 1997; Lin et 
al., 1998; Mastberger et al., 2000) arrests the cell cycle phase G2/M by blocking the mitotic 
spindle formation (Harmsma et al., 2004). 
2. Aim 
2.1 Comparison of the effects of Viscum album QuFrF extract with those of Vincristine.  
2.2 Mode of action of Viscum album QuFrF extract and Vincristine. 
2.3 To assess the effective doses of Viscum album QuFrF extract and to transfer these doses 
to the in vivo situation.  
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3. Materials and methods  
3.1 Test substances 
Viscum album QuFrF (VAQuFrF) extract was obtained from the Hiscia Institute (Arlesheim, 
Switzerland). According to the manufacturer the aqueous unfermented solution of extract 10 
mg/ml contains 2 µg lectin and 10 µg viscotoxin. Vincristine sulfate salt was obtained from 
Sigma GmbH (Schnelldorf Germany, No 8879). Recombinant human interleukin-6  (rh IL-6) 
was obtained from R & D Systems (No. 206-IL, United Kingdom) and reconstituted in 
phosphate-buffered saline with 0.18% bovine serum albumin. 
3.2 Cells and culture condition 
Human myeloma cell lines (MOLP-8, LP-1, RPMI-8226, OPM-2, U-266, COLO-677, KMS-12-
BM, were obtained from DSMZ (Braunschweig, Germany). Five cell lines derived from 
blood, COLO-677 from lymph node, KMS-12-BM from bone marrow. The cells were 
cultivated in RPMI 1640 supplemented with 10-20% foetal calf serum, 2mM L-glutamine 
and 1 % gentamicin in a  humidified atmosphere with 5% C02  at 37°C. The doubling times 
of tumour cell lines were between 35 and 96 hours. For the measurement of the parameters 
the cell cultures were used within 4-6 weeks after thawing. 
3.3 Treatment of cells with VAQuFrF extract or vincristine   
a. To measure viability, cytokine production, membrane expression of IL-6 receptor, cell 
cycle phases and apoptosis /necrosis the cells were cultured at a density of 0.5-0.7x106 
cells/ml, except for COLO-677 (0.2x106 cells/ml).  After 24 hours the cells were 
incubated with VAQuFrF extract or Vincristine  (doses: 0, l0, 50 or 100 µg/106 cells/ml). 
The parameters were measured after 24, 48 and 72 hours. 
b. To measure proliferation the cells were cultured at a density of 0.5-0.7x105 cells/100 µl, 
except for COLO-677 (0.2x105 cells/100 µl). After 24 hours the cells were incubated with 
VAQuFrF extract or Vincristine (doses: 0, 1, 5, 10 µg/105 cells/100l). The parameter 
was measured after 24, 48 and 72 hours.  
3.4 Treatment of cells with Interleukin-6 
a. To measure viability, cytokine production, membrane expression of IL-6 receptor, cell 
cycle phases and apoptosis /necrosis the cells were cultured at a density of 0.5-0.7x106 
cells/ml, except for COLO-677 (0.2x106 cells/ml).  After 24 hours the cells were 
incubated with IL-6 (dose: 5 ng/106cells/ml). The parameters were measured after 24, 
48 and 72 hours.  
b. To measure proliferation the cells were cultured at a density of 0.5-0.7x105 cells/100 µl, 
except for COLO-677 (0.2x105 cells/100 µl). After 24 hours the cells were incubated with 
IL-6 (dose: 0.5 ng/105cells/100l). The parameter was measured after 24, 48 and 72 hours.  
3.5 Measurement of viability 
The viabilities of the cultivated tumour cells were determined by 7-aminoactinomycin D (7-
AAD), to exclude the non-viable cells in flow cytometric assays. The values are given in %. 
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3.6 Measurement of cytokine production 
The IL-6 production or IL-10 production in the supernatant of the cultured cells was 
determined by chemiluminescent immunometric assay. The lowest detectable level was 2 
pg/ml or 5 pg/ml. 
3.7 Measurement of membrane expression of IL-6 receptor 
For immunofluorescence staining 3x105 cells/100 l were incubated with 20 l 
phycoerithrin (PE) conjugated monoclonal antibody (CD 126, Immunotech, France) for 30 
min at 4 ◦C. Then the cells were washed, sedimented and analysed in the FACSCalibur 
flow cytometer. For the expression of the membrane IL-6R (CD 126) the signal intensity 
(geometric mean of the fluorescence intensity x counts) was used as parameter. The signal 
intensity of the treated samples was compared with that of untreated samples, which 
were taken as 100%. 
3.8 Measurement of the cell cycle phases 
The cell cycle phases GO/GI, S, G2/M were assessed using the cycle test plus DNA reagent 
kit on a flow cytometer (BD, BioSciences, San Jose, USA  No 340242). Briefly: 5x105 cells 
were incubated at room temperature with trypsin buffer and additionally with trypsin 
inhibitor+RNAse buffer. The values are expressed in percentage of total viable cell number 
(100%). 
3.9 Measurement of apoptosis and necrosis 
Apoptosis was measured using Annexin V-FITC (BD Biosciences Pharmingen, San Diego, 
USA No 556 570). Necrosis was measured using propidium iodide (PI). Briefly: 1x105 cells 
were incubated with Annexin V-FITC or PI at room temperature in the dark. Thereafter the 
samples were analysed in a flow cytometer. Apoptotic cells: Annexin V-FITC positive and PI 
negative. Necrotic cells: Annexin V-FITC positive and PI positive. The values are given in 
percent of total cell number.  
3.10 Measurement of the proliferation 
The proliferation was assessed using cell proliferation reagent WST-1 (Roche, Mannheim, 
Germany, No 1644 807). The colorimetric assay is based on the reduction of the tetrazolium 
salt WST-1 by viable cells. The reaction produces the soluble formazan salt. The quantity of 
the formazan dye is directly correlated to the number of the metabolically active cells. The 
proliferation rate was measured 1, 2 and 4 h after incubation with the reagents at time points 
24, 48 and 72 h. The upper limit of the absorbance was 2.0–2.1. The intra-sample variance of 
the untreated cells was <10% (3–8%). 
3.11 Statistical analysis 
Three to four independent measurements were carried out. For the evaluation of the 
parameters the Mann-Whitney U-test was used. The limit of significance was taken as 
P<0.05.  
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4. Results 
4.1 Production of Interleukin-6 in supernatant of human multiple myeloma cells 
Objectives: (a) spontaneous production, (b) production after treatment with VAQuFrF  or 
Vincristine. 
Table 1 presents the values of IL-6 in myeloma cell line MOLP-8, LP-1, RPMI-8226, OPM-2, 
COLO-677. None of the five multiple myeloma cell lines produced Interleukin-6 
spontaneously. This means that all the investigated cell lines are IL-6 independent or have 
autocrine/paracrine regulation mechanisms. In case of an autocrine regulation mechanism 
the cytokine is produced endogenously and affects its membrane receptor directly. In case 
of paracrine regulation mechanism the exogenous cytokine also affects the membrane 
receptor. In two cell lines (RPMI-8226 and OPM-2) exogenous IL-6 led to a high expression 
of membrane IL-6R and enhanced levels of sIL-6R in the supernatant (Kovacs, 2003; and 
results are not shown) indicating a paracrine regulation mechanism. 
 
Maeasurements at 24 and 48 hours after tretment with VAQufrF extractor Vincristine. Dose=50 µg/106 
cells in both cases.ND = not detectable. 
Table 1. Production of Interleukin-6 in human multiple myeloma cell lines. 
Treatment with VAQuFrF extract (dose: 50 µg/106 cells) and with Vincristine (dose: 50 
µg/106 cells) also did not lead to IL-6 production in the five multiple myeloma cell lines. 
These results confirm the findings of previous studies (Kovacs et al., 2006; Kovacs, 2010b).     
4.2 Production of interleukin-10 in supernatant of human multiple myeloma cells 
Objectives: (a) spontaneous production, (b) production after treatment with IL-6 (dose: 
5ng/106 cells), (c) production after treatment with VAQuFrF or Vincristine (dose: 50 µg/106 
cells for both substances), (d) after treatment with IL-6+VAQuFrF or IL-6+Vincristine (doses: 
5 ng/106 cells +50 µg/106 cells in each case).  For the combined treatment IL-6 was added 2 
hours before the test substances. 
Table 2 presents the production of Interleukin-10 in five human multiple myeloma cell 
lines. Spontaneous IL-10 production was found in 4/5 cell lines: MOLP-8, LP-1, RPMI-8226, 
COLO-677, however the cell lines MOLP-8 and COLO-677 secreted IL-10 not every time 
confirming the findings of previous study (Kovacs, 2010a). IL-6 led to a marked increase of 
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IL-10 production (up to 946 pg/ml) in 5/5 cell lines. VAQuFrF extract and Vincristine 
reduced the spontaneous IL-10 production in MOLP-8, LP-1 and COLO-677 to non-
detectable amounts. 
With IL-6+VAQuFrF or IL-6+Vincristine the values were markedly lower after addition of 
IL-6 but higher than without IL-6 treatment. VAQuFrF and Vincristine reduced the induced 
IL-10 production to the same degree in cell lines RPMI-8226 and LP-1. In the cell lines OPM-
2, MOLP-8, COLO-677 the extract of VAQuFrF inhibited the IL-10 production weaker than 
Vincristine.  
 
Maesurements at 24 and 48 hors after tretment. IL-6:5ng/106 cells.VAQuFrF and Vincristine: 50 µg/106 
cells. Range of 4 independent measurements. ND=not detectable 
Table 2. Production of Interleukin-10 (pg/ml)in human multiple myeloma cell lines. 
 
The values are presented in percentage. Range of four independent measurements. 
Table 2.A. Viability of human multiple myeloma cells (cell lines see Table 2). 
The IL-10 production was measured at 24 and 48 after incubation with IL-6. The results 
show that in tumour cell lines MOLP-8 and RPMI-8226 the IL-10 production was high 
during the two days. In the other three cell lines the production decreased slightly at 48 h. 
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Table 2/A. presents the range of cell viability without treatment and after treatment with the 
test substances: L-6, VAQuFrF extract and Vincristine. The viability of the untreated MM 
cells was different: LP-1>RPMI-8226>COLO-677>MOLP-8>OPM-2. The both test substances 
impaired the viability to different degrees. 
IL-6 does not alter the viability, confirming the findings of previous investigations (Kovacs, 
2006b, 2010a). It was reported that IL-6 enhances survival of the myeloma cells because it 
inhibits apoptosis of induction of the anti-Fas (Nordan & Potter, 1986; Hata et al., 1995).  
Summarised: The results indicate that the effect of the both test substances on the IL-10 
production is due to their apoptotic/necrotic effects. It is possible that VAQuFrF and 
Vincristine could also impair the membrane expression of IL-10 receptor. To explain this 
hypothesis further experiments are necessary.   
4.3 The effect of Interleukin-6, VAQuFrF and IL-6+VAQuFrF on the membrane 
expression of Interleukin-6 receptor in human multiple myeloma cells 
Objectives: (a) in untreated cells, (b) after treatment with IL-6 (dose: 5 ng/106cells), (c) after 
treatment with VAQuFrF (dose: 50 µg/106 cells), (d) after treatment with IL-6+ 
VAQuFrF(dose: 5 ng/106 cells+50 µg/106 cells). For the combined treatment IL-6 was added 
2 hours before the test substance. For the expression of the membrane IL-6R the signal 
intensity (geometric mean of the fluorescence intensity x counts) was used as parameter. 
This parameter was measured at 24 and 48 hours after incubation. The signal intensity of the 
treated samples, expressed in percentage was compared with that of untreated samples, 
which were taken as 100%.  
Table 3 presents the mean values of the membrane expression of Interleukin -6 receptor in 
the cell lines LP-1, RPMI-8226 and OPM-2.  
 
Measurements at 24 h after treatment.    Measurements at 48 h after treatment. 
The mean values of three independent measurementa are expressed in percentage of untreated samples 
(100). a=p<0.05 vs.untreated samples, b=p<0.05 vs. with IL-6 treated samples. 
Table 3. Membrane expression of Interleukin-6 receptor in human multiple myeloma cell 
lines.  
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The surface expressions of IL-6R in untreated cells of all three cell lines were in the  
similar range (results are not shown). Exogenous IL-6 increased the membrane expression 
its receptor significantly (P<0.05). VAQuFrF reduced the membrane expression markedly  
in LP-1 and RPMI-8226 (P<0.05), it had no effect in OPM-2. With IL-6+VAQuFrF  
the values were lower than with IL-6 (P<0.05), but higher than after treatment with 
VAQuFrF.  
In cell lines MOLP-8, COLO-677 and KMS-12-BM exogenous IL-6 led to down-regulation of 
its receptor, signalling the possible process of endocytosis (results are not shown). It is 
interesting that all three cell lines in which IL-6 upregulated its membrane receptor sourced 
from blood. To investigate of the membrane expression of IL-6 receptor in the cell lines 
MOLP-8, COLO-677 and KMS-12-BM additional experiments are planned. 
4.4 Inhibition of proliferation of multiple myeloma cells (cytostatic effect). Induction of 
apoptosis and necrosis in multiple myeloma cells (cytocidal effect) 
Figure 1 and Figure 2 present the mean values of the proliferation and those of 
apoptosis/necrosis in six human multiple myeloma cell lines treated with IL-6 or 
VAQuFrF or Vincristine. The cell lines MOLP-8, LP-1, RPMI-8226, OPM-2 sourced from 
blood, COLO-677 which is a derivative of RPMI-8226 from lymph node, KMS-12-BM from 
bone marrow.  
To measure the proliferation the following doses were applied (1) IL-6: 0.5 ng/105 cells, (2) 
VAQuFrF or Vincristine: 1, 5, 10 µg/105 cells. To measure apoptosis/ necrosis (1) IL-6: 5 
ng/106 cells, (2) VAQuFrF or Vincristine; 10, 50, 100 µg/106 cells. The parameters were 
measured at 24, 48 and 72 hours after incubation with the test substances.  
Proliferation: The values of the treated samples are expressed as percentages of the 
untreated samples and are the average of four independent experiments. Significance was 
assessed versus untreated samples (100%). 
Apoptosis/necrosis: The values are expressed as percentage of total cell numbers and are 
the average of four independent experiments. In the untreated samples the percentage of 
apoptotic cells lay in the range of 5-38%, that of necrotic cells 10-35% during 72 hours. There 
were big differences between the tumour cell lines.  
4.4.1 MOLP-8  
Proliferation: IL-6 increased the proliferation on average up to 130-155%. Comparison of 
VAQuFrF with Vincristine: 24 and 48 hours after incubation VAQuFrF at the dose of 5 and 
10 µg/105 cells was more effective than Vincristine. 72 hours after there was no difference 
between the substances in any dose.  
Apoptosis/necrosis: In the untreated tumour cells the values of apoptosis lay either in the 
range of necrosis or above them. IL-6 treatment did not impair either the apoptosis or 
necrosis. To measure the effects of the two substances on the apoptosis/necrosis we applied 
ten times less doses. VAQuFrF increased the apoptosis and necrosis at 5 and 10 µg/106 cells 
(P<0.05 and P<0.01). Vincristine had the same effect as VAQuFrF. 
www.intechopen.com
 
Pharmacology  
 
596 
 
Fig. 1. The effects of IL-6, VAQuFrF extract and Vincristine  on the proliferation and on 
apoptosis/necrosis in human multiple myeloma cell lines MOLP-8, LP-1 and RPMI-8226. The 
mean values of four independent experiments are expressed as percentage of untreated samples 
(100%). Proliferation=105 cells. Apoptosis/necrosis=106 cells. ●- - -● apoptotic cells, ●––● 
necrotic cells. +P<0.05, *P<0.01 compared with untreated samples (Mann-Whitney U-test). 
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4.4.2 LP-1 
Proliferation: With IL-6 the proliferation rate lay on average between 128-162% during 72 
hours. VAQuFrF at the dose of 10 µg/105 cells inhibited the proliferation more effectively 
(P<0.01) than Vincristine. 
Apoptosis/necrosis: In the untreated cell the values of apoptosis lay in the range of necrosis. 
There was no difference between the values of untreated and with IL-6 treated cells. 
VAQuFrF did not greatly alter the apoptosis during the investigation time. There was a 
necrotic effect with a dose dependence from 50 up to 100 µg/106 cells (P<0.05). Vincristine 
increased the number of apoptotic cells and that of necrotic cells (P<0.05), however without 
dose dependence. The number of necrotic cells was higher than that of apoptotic cells at 
each dose after 48 and 72 hours (P<0.05 and P<0.01).    
4.4.3 RPMI-8226 
Proliferation: IL-6 increased the proliferation on average up to 105-141%. 
The test substances inhibited the proliferation: After 24 and 48 hours VAQuFrF in dose of  
10 µg/105 cells was more effective than Vincristine (P<0.01). In lower doses (5 µg/105 cells 
and 1 µg/105 cells) VAQuFrF had the same effect as Vincristine. 
Apoptosis/necrosis: The values of apoptosis in untreated cells lay below the necrosis.  There 
were no differences between the values of cells treated with IL-6 and that those of untreated 
cells. 
VAQuFrF and Vincristine did not alter the apoptosis. At 72 hours after treatment with both 
substances he numbers of necrotic cells was higher than those of apoptotic cells at each dose 
(P<0.05 and P<0.01).  
4.4.4 OPM-2 
Proliferation: IL-6 increased the proliferation on average between 110-130%. Comparison of 
VAQuFrF with Vincristine: The inhibitory effect of VAQuFrF was weaker than that of 
Vincristine at each dose and at investigated time point. Additional investigation indicate 
that higher doses increase the effect of VAQuFrF (results are not presented). 
Apoptosis/necrosis: In the untreated cells the values of apoptosis lay in the range of 
necrosis. IL-6 did not impair either the apoptosis or necrosis of the cells. None of the test 
substances altered the apoptosis. Vincristine increased markedly the number of necrotic 
cells between 10 and 100 µg/106 cells without dose dependence after 72 hours of treatment. 
VAQuFrF was ineffective.  
4.4.5 COLO-677 
Proliferation: With IL-6 the values of proliferation lay on average between 110-115%. 
The inhibitory effect of VAQuFrF was weaker than that of Vincristine in doses of 1 and 5 
µg/105 cells.  At the dose of 10 µg/105 cells the anti-proliferative effects of VAQuFrF and 
Vincritine was the same at each investigated time point. 
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Fig. 2. The effects of IL-6, VAQuFrF extract and Vincristine on the proliferation and on the 
apoptosis/necrosis in human multiple myeloma cell lines OPM-2, COLO-677 and KMS-12-
BM. The mean values of four independent experiments are expressed as percentage of 
untreated samples (100%). Proliferation=105 cells. Apoptosis/necrosis=106 cells. ●- - -● 
apoptotic cells, ●––● necrotic cells. +P<0.05, *P<0.01 compared with untreated samples 
(Mann-Whitney U-test). 
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Apoptosis/necrosis: In the untreated tumour cells the values of apoptosis lay either in the 
range of necrosis or below them. There was no alteration after treatment with IL-6. 
VAQuFrF did not alter the apoptosis. There was a necrotic effect with a dose dependence 
(from 50 up to 100 µg/106 cells) (P<0.05). Vincristine increased the number of apoptotic cells 
(P<0.05). The number of necrotic cells was higher than that of apoptotic at each dose and at 
each time point (P<0.05 and P<0.01). The apoptotic /necrotic effects of Vincristine were not 
dose-dependent. 
4.4.6 KMS-12-BM 
Proliferation: IL-6 increased the proliferation on average between 108 and 135%. VAQuFrF 
inhibited the proliferation only in dose of 10 µg/105 cells after 48 and 72 hours. Vincristine 
inhibited the proliferation markedly however without dose dependence at each dose and at 
each investigated time point.  
Apoptosis/necrosis: The values of apoptosis in untreated cells lay above the values of 
necrosis. IL-6 did not alter the apoptosis and necrosis. VAQuFrF did not impair either the 
apoptosis or the necrosis in this cell line. Vinristine was effective in KMS-12-BM: The 
number of apoptotic/necrotic cells was significantly higher (P<0.01) at each time point, but 
without dose dependence. 
It was reported that that inhibition of cell proliferation is a stronger prognostic indicator 
than the apoptosis (Stokke et al., 1998). There is a quantitative correlation between the 
inhibition of proliferation and apoptosis in lymphoma cells (Leoncini, et al., 1993).  
Chemotherapeutic agents influence apoptosis through a mitochondrial pathway (Oancea, et 
al., 2004). Multiple myeloma cells overexpress Bcl-2, a mitochondrial membrane protein 
which suppresses apoptosis (Chanen-Khan, 2004; Tsujimoto & Shimizu, 2007). VAQuFrF 
decreases the levels of Bcl-2 in B and T lymphocytes (Duong Van Huyen et al., 2001). 
Summarised: In this study the apoptotic/necrotic effect of Vincristine was more marked 
than its proliferative effect in all cell lines. There was no dose dependence between 10, 50 or 
100 µg/106 cells/ml in both parameters. It is possible that Vincristine impairs the 
proliferation and apoptosis/necrosis with dose dependence only in a lower dose range.  
VAQuFrF first inhibits the proliferation and then the cells die by apoptosis and/or necrosis 
in the MM cell lines LP-1, RPMI-8226 and COLO-677, confirming the findings with RPMI-
8226 presented in a previous study (Kovacs et al., 2006a). The inhibitory effect of VAQuFrF 
was markedly weaker than that of Vincristine in cell lines OPM-2 and KMS-12-BM at each 
dose and at investigated time point.  
4.5 The effect of VAQuFrf on the proliferation of cells with high proliferation rate 
The effect of VAQuFrF with doses of 5 and 10µg/105 cells was investigated in cell line RPMI-
8226 with high proliferation rate, which remained unaltered during 2-3 days. VAQuFrF was 
more effective in cells having high proliferation rates than in those with low proliferation 
rates (Kovacs et al., 2006a). Recently the same findings were observed in cell lines LP-1 and 
OPM-2 (results are not shown). 
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4.6 The effect of combined treatment with Interleukin-6+VAQUFrF on the proliferation 
in human multiple myeloma cells 
The cell lines MOLP-8, LP-1, RPMI-8226 and COLO-677 were treated with Interleukin-
6+VAQuFrF for 24, 48 and 72 hours. To measure the proliferation the following doses were 
used: 0.5 ng/105 cells + 1, 5, 10 µg/105 cells. For the combined treatment IL-6 was added to 
the cell cultures 2 hours before VAQuFrF. For comparison the cell lines were treated only 
with IL-6 or only with VAQuFrF. 
Figure 3 presents the range of values expressed in percentage compared with untreated 
samples (100%). As expected, VAQuFrF inhibited the spontaneous proliferation markedly in 
all cell lines. The effect was dose-dependent. IL-6 led to enhanced proliferation in each case. 
We expected that with the combined treatment the values will be lower than after single 
treatment of IL-6, but higher than after single treatment of VAQuFrF. This situation has been 
found only in cell lines MOLP-8 and LP-1 for dose 1µg/105 cells. It is suggested that the 2 
hours pre-treatment with IL-6 is too short.  
 
Fig. 3. The effect of combined treatment with IL-6 + VAQuFrF on the proliferation in human 
multiple myeloma cells. IL-6=0.5 ng/105 cells. 
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4.7 Investigation of cell cycle phases in human multiple myeloma 
Cell division consists of mitosis (M) and interphase, which divides into phases G1, G2, and 
S. Non dividing cells are in the stable resting phase, called the G0 phase.  The blockade in 
the cell division leads to an arrest in the different cycle phases. This arrest appears as an 
accumulation of the tumour cells.  
The following cell lines: were investigated: MOLP-8, LP-1, RPMI-8226, OPM-2, U-266, 
COLO-677, KMS-12-BM. The myeloma cells were treated (a) with IL-6 (dose: 5 ng/106 cells) 
(b) with VAQuFrF and with Vincristine (doses: 10, 50, 100 µg/106 cells). The investigation 
was carried out 24, 48 and 72 hours after treatment.  
Table 4 presents the range of the values of untreated cells in different cell cycle phases in 
percentage in the total viable cell number (100%) 24 hours after treatment. Table 5 presents the 
mean values resp. the accumulation of treated cells 24 hours after treatment. For the cell lines 
RPMI-8226, OPM-2 and U-266 the presented values signalize the effects 48 and 72 hours after 
treatment with VAQuFrF or Vincristine. For a significant increase or decrease, the percentage 
of the cell number of treated samples was compared with those of untreated samples.  
 
 
Measurements at 24 hour after incubation. Values are expressed in percentage of total viable cell 
number (100%). Range of four independent experiments. 
Table 4. Values of untreated human multiple myeloma cells in different cell cycle phases. 
Phases GO/G1: IL-6 did not affect this cell cycle phase. VAQuFrF led to an accumulation of 
cells in cell line MOLP-8, LP-1 and in KMS-12-BM (p < 0.05 and p < 0.01). Vincristine had 
effect in the cell lines MOLP-8 and LP-1 (p < 0.05). The both substances were effective at 
each time point. 
Phase S: With IL-6 the number of cells was increased markedly in all cell lines during 72 
hours except with OPM-2 and KMS-12-BM. In these cell lines there was no effect at 72 hours. 
VAQuFrF increased the cell number (p < 0.01) in RPMI-8226 and U-266 (p<0.05), Vincristine 
in RPMI-8226, OPM-2 and U-266 (p < 0.01 and p < 0.05). Both substances were effective only 
at 48 and 72 hours after incubation.   
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Treatment with IL-6(5ng/106 cells) or VAQuFrF or Vincristine(10,50,100 µg/106 cells); The 
investigation was carried out 24, 48 and 72 hours after treatment. Evaluation of three or four 
independent experiments =accumulation. The numbers present the mean values in percentage. 
Table 5. Accumulation of human multiple myeloma cells in different cell cycle phases. 
Phases G2/M: IL-6 treatment led to accumulation of cells in LP-1, RPMI-8226 and OPM-2 after 
48 and 72 hours. VAQuFrF was effective in COLO-677 (p < 0.05). Vincristine led to marked 
increase of the cell numbers in cell lines RPMI-8226, COLO-677 and KMS-12-BM (p < 0.01).  
With IL-6 the cell number of each cell line was enhanced in the S phase and in some cell 
lines in the G2/M phase too. This means that either the DNA synthesis of the cells is 
increased or the cells are arrested in these cell cycle phases.  In this investigation IL-6 led to 
high proliferation in all cell lines indicating an increased DNA synthesis. This could lead 
with to arrest in the cycle phase G2/M.  In fact we found the accumulation of cells 48 and 72 
hours after treatment in some cell lines. 
Vincristine blocks the mitotic process by binding to tubulin leading to an arrest of the cycle 
phase in G2/M (El Alaaoui et al., 1997; Lin et al., 1998). In this study Vincristine led to an 
accumulation of the cells in cycle phase G2/M in only three out of seven multiple myeloma 
cell lines. It was effective in S and in G0/G1 phases of five cell lines, indicating that 
Vincristine also affects these cycle phases. It is interesting that it was effective both in the S 
and in G2/M cycle phases of the cell line RPMI-8226. VAQuFrF extract had the same effects 
as Vincristine in five out of seven tumour cell lines; however in a higher dose range. We 
postulated that different tumour cell lines from the same disorder (multiple myeloma) show 
a different sensitivity to Vincristine or VAQuFrF. 
The inhibition of the G0/G1 phases in different malignancies correlates with anti-
proliferative substances (El-Sherbiny et al., 2000; Pellizaro et al., 2008). In fact VAQuFrF 
blocked the cells in the G0/G1 phases in cell lines MOLP-8 and LP-1 and also inhibited the 
cell proliferation. 
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5. Summary and conclusion 
In this experimental study we compared Viscum album (Mistletoe) extract and Vincristine 
in several human multiple myeloma cell lines using the parameters: (a) the IL-6 production, 
(b) the IL-10 production, (c) the expression of membrane IL-6 receptor, (d) the proliferation, 
(e) the apoptosis/necrosis, (f) the cell cycle phases.  The following parameters were 
measured in a “package” i.e. they measured simultaneously: (a) the IL-6 production, (b) the 
IL-10 production, (c) the proliferation, (d) the apoptosis/necrosis.   
The parameters were measured at different times (24, 48 and 72 hours) after incubation with 
VAQuFrF and Vincristine. Interleukin-6 is a major proliferative factor for the malignant 
plasma cells (multiple myeloma cells). Therefore this cytokines was measured parallel to the 
test substances. 
Viscum album QuFrF (VAQuFrF) is an experimental drug that is not yet used in the 
treatment of tumour patients.  For this reason it was necessary and important to compare 
with a well-known clinic-substance. Vincristine is used mainly in combination with other 
chemotherapeutic substances in the therapy of multiple myeloma. 
5.1 Key results 
a. Interleukin-6 leads to a markedly increased IL-10 production. Interleukin--6 
upregulates markedly the expression of its membrane receptor (IL-6R). IL-6 increases 
the proliferation and it is effective in the S cell cycle phase. IL-6 does not affect the 
apoptosis/ necrosis. 
b. Neither VAQuFrF nor Vincristine produce IL-6 or lead to an enhanced IL-10 production 
in any cell line. VAQuFrF and Vincristine inhibits the spontaneous IL-10 production. 
Both substances counteract the increased IL-10 production induced by IL-6. The effects 
of the two substances are comparable. The results indicate that the effect of the both test 
substances on the IL-10 production is due to their apoptotic/necrotic effects.  
c. VAQuFrF inhibits the membrane expression of IL-6 receptor. VAQuFrF counteracts the 
enhanced membrane expression of this receptor induced by IL-6. 
d. The cytocidal effect of Vincristine is more marked than its cytostatic effect in all cell 
lines.  
The effect of VAQuFrF focuses on the inhibition of proliferation (cytostatic effect). 
VAQuFrF first inhibits the proliferation and then the cells die by apoptosis and/or 
necrosis. 
e. VAQuFrF inhibits the proliferation in cells with high proliferation rate more 
effectively than in those with low growth rate. 
f. Cell cycle phases: VAQuFrF extract has the same effect as Vincristine in five out of 
seven tumour cell lines, however in a higher dose range. 
The findings indicate that VAQuFrF extract could be a novel drug in the therapy of multiple 
myeloma. 
To assess the effective doses of Viscum album QuFrF extract and to transfer these doses 
to the in vivo situation.  
The Viscum album QuFrF (VAQuFrF) is an aqueous and unfermented extract of mistletoe 
plants growing in the oak tree. It contains 2 µg lectin and 10 µg viscotoxin in 10 mg/ml. It 
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was tested in dose range of 10, 50, 100 µg/106 cells. 10 µg extract contains 0.002 µg lectin + 
0.01 µg viscotoxin, 50 µg extract contains 0.01 µg lectin + 0.05 µg viscotoxin, 100 µg extract 
contains 0.02 µg lectin + 0.1 µg viscotoxin. 
Dosage of Vincristine in the therapy for multiple myeloma: In combination with other 
chemotherapeutic agents as a part of the VAD regimen 0.4 mg/day intravenously (400 
µg/day). In these experimental studies Vincristine was applied in dose range of 10, 50, 100 
µg/106 cells. The effects of Vincristine on the proliferation and the apoptosis/necrosis were 
in each cell line without dose dependence. This means that these doses lay in a saturation 
range. It is planned to investigate the effects of Vincristine in a lower dose range. 
The efficient dose range for VAQuFrF lies between 50 and 100 µg/106 cells (0.01µg lectin + 0.05 
µg viscotoxin and 0.02 µg lectin + 0.1 µg viscotoxin). These date concern the cell lines LP-1, 
RPMI-8226 and COLO-677. For cell lines OPM-2, KMS-12-BM the dose range lies higher. In 
MOLP-8 cell line VAQuFrF inhibits the proliferation more effectively than Vincristine. 
Our findings suggest that the in vivo effective (active) dose for VAQuFrF will  be about 10-
20 times higher than that of Vincristine. 
6. Future research 
1. Viscum album (VA) QuFrF extract contains two active components: mistletoe lectins (I, 
II, III) and viscotoxins.  
Question: Which component is responsible for the effects of this extract? Is this the 
lectin(s) or viscotoxin or both? Further study is planned to clarify this question. 
The non-fermented preparation from VAQuFrF extract contains 2 µg lectin and 10 µg 
viscotoxin in 10 mg/ml (ratio between lectin and viscotoxin: 0.2).  
The ratio between lectin and viscotoxin from the fermented preparations is 0.06 
respectively 0.08. The fermented preparations are used either alone or in combination 
with chemo /radiotherapy in the treatment of tumour patients. The extract presented in 
this study is an experimental drug that is not yet used in the treatment of tumour patients. 
2.  The results presented in this study indicated that VAQuFrF could effect the membrane 
expression of IL-6 receptor by antagonism. Question: Is this substance a competitive- or 
a non-competitive antagonist?  Additional experiments will give answer to this 
(important) question. 
3. To investigate more human multiple myeloma cell lines. 
To investigate tumour cells isolated from bone marrow of patients with multiple 
myeloma. 
4. To investigate the anti-proliferative and apoptotic/necrotic effects of Vincristine in a 
lower dose range, respectively the anti-proliferative and apoptotic/necrotic effects of 
VAQuFrF extract in a higher dose range.  
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